Phuturdex › Diseases › Cardiomyopathies
Drugs in development · updated 30 October 2026
Cardiomyopathies: drugs in development
As of 30 October 2026 there are 22 active clinical trials (recruiting or ongoing, phases I–III) on 23 drugs for cardiomyopathies. 10 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MelatoninSlenyto®, Circadin® | III | 1 | NCT06846086 |
| NTLA-2001 | III | 1 | NCT06128629 |
| Nucresiran | III | 1 | NCT07052903 |
| LX2006 | I–II | 2 | NCT05445323 |
| ATR 1072 | I–II | 1 | NCT07738107 |
| LX2020 | I–II | 1 | NCT06109181 |
| Nicorandil Oral Tablet | II | 1 | NCT07897409 |
| RP-A501 | II | 1 | NCT06092034 |
| [14C]HRS-1893 | I | 1 | NCT07656779 |
| ATI-105 | I | 1 | NCT07869654 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AcoramidisAttruby®, Beyonttra® | III | 2 | NCT07116473 |
| VutrisiranAmvuttra® | III | 2 | NCT06679946 |
| ColchicineColchicin, Lodoco® | III | 1 | NCT06158698 |
| BivalirudinAngiomax Rtu®, Bivalirudin In 0.9% Sodium Chloride® | II | 1 | NCT06080074 |
| DeferasiroxJadenu Sprinkle®, Jadenu® | II | 1 | NCT07023666 |
| DeferiproneFerriprox®, Deferiprone Lipomed® | II | 1 | NCT07023666 |
| DeferoxamineDesferal® | II | 1 | NCT07023666 |
| DoxorubicinAdriamycin, Doxorubincin | II | 1 | NCT07897409 |
| HeparinUnfractionated heparin, Heparin Sodium Preservative Free® | II | 1 | NCT06080074 |
| SimvastatinFlolipid®, Zocor® | II | 1 | NCT06632834 |
| TrametinibMekinist®, Spexotras® | II | 1 | NCT06555237 |
| Ammonium ChlorideLac-Hydrin®, Ammonium Chloride 0.9% In Normal Saline® | I | 1 | NCT06209359 |
| PrednisonePredinisone, Cortancyl | I | 1 | NCT05302271 |
Sorted by most advanced phase and number of active trials.
All 23 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Hypertrophic cardiomyopathy 16 drugs
- Myocarditis 8 drugs
- Dilated cardiomyopathy 7 drugs
- Heart failure 104 drugs
- Inflammation 85 drugs
- Arrhythmogenic right ventricular cardiomyopathy 5 drugs
- Myocardial reperfusion injury 3 drugs
- Myocardial infarction 26 drugs
- Coronary artery disease 34 drugs
- Arterial hypertension 119 drugs
- Cardiovascular disease 71 drugs
- Neoplasm 671 drugs
Broader categories
- Cardiovascular disease 71 drugs
- Heart disease 17 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Metabolic disease 30 drugs
- Nutritional and metabolic diseases 5 drugs
- Genetic disease 33 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D009202 “Cardiomyopathies”.